November 17, 2017 Acad, Gov/Utilities

FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma

Basel, 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in... Read more

November 16, 2017 Acad, Gov/Utilities

FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors

Basel, 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors First new medicine in nearly 20 years to treat people with haemophilia A with inhibitors Hemlibra substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) Roche (SIX: RO, ROG;... Read more

November 14, 2017 Acad, Gov/Utilities Lab Top-10 M&A, Partnerships Mass Spectrometry

Shimadzu Supports New Medicinal Plant Chemistry Program at Northern Michigan University

November 14 2017 Shimadzu Scientific Instruments (SSI), the leading provider of cannabis testing instruments, and Northern Michigan University (NMU) announce a collaborative relationship in support of NMU’s new 4-year undergraduate degree program in Medicinal Plant Chemistry. This program is intended to complement the emerging cannabis economy with a specific focus on laboratory analysis, experimental horticulture,... Read more

November 13, 2017 Acad, Gov/Utilities Atomic Spectroscopy Cell Analysis Tools Lab Top-10 PR/Corporate

Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang

Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research SANTA CLARA, Calif., November 12, 2017 Agilent Technologies Inc. (NYSE: A) today announced that Professor Jiandong Jiang has received an Agilent Thought Leader Award in support of his... Read more

November 7, 2017 Acad, Gov/Utilities

FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation

Basel, 07 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced... Read more

November 7, 2017 Acad, Gov/Utilities

FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer

Basel, 07 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food... Read more

November 1, 2017 Acad, Gov/Utilities PR/Corporate Product Launch

Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting

Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more

November 1, 2017 Acad, Gov/Utilities PR/Corporate Product Launch

Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting

Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more